Suppr超能文献

PREDIMED试验(地中海饮食预防研究)中的血浆神经酰胺、地中海饮食与心血管疾病发病率

Plasma Ceramides, Mediterranean Diet, and Incident Cardiovascular Disease in the PREDIMED Trial (Prevención con Dieta Mediterránea).

作者信息

Wang Dong D, Toledo Estefanía, Hruby Adela, Rosner Bernard A, Willett Walter C, Sun Qi, Razquin Cristina, Zheng Yan, Ruiz-Canela Miguel, Guasch-Ferré Marta, Corella Dolores, Gómez-Gracia Enrique, Fiol Miquel, Estruch Ramón, Ros Emilio, Lapetra José, Fito Montserrat, Aros Fernando, Serra-Majem Luis, Lee Chih-Hao, Clish Clary B, Liang Liming, Salas-Salvadó Jordi, Martínez-González Miguel A, Hu Frank B

机构信息

From Department of Nutrition (D.D.W., W.C.W., Q.S., Y.Z., M.G.-F., C.-H.L., F.B.H.); Department of Epidemiology (D.D.W., W.C.W., L.L., F.B.H.), Department of Biostatistics (B.A.R., L.L.), Department of Genetics and Complex Diseases (C.-H.L.), Harvard T.H. Chan School of Public Health, Boston, MA; Department of Nutrition (M.A.M.-G.), Department of Preventive Medicine and Public Health, University of Navarra, Pamplona, Spain (E.T., C.R., M.R.-C., M.A.M.-G.); Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain (E.T., C.R., M.R.-C., M.A.M.-G.); CIBER Fisiopatología de la Obesidad y Nutrición, Instituto de Salud Carlos III, Madrid, Spain (E.T., C.R., M.R.-C., D.C., M.F., R.E., E.R., J.L., M.F., F.A., L.S.-M., J.S.-S., M.A.M.-G.); Jean Mayer US Department of Agriculture Human Nutrition Research Center on Aging at Tufts University and Tufts University Friedman School of Nutrition Science and Policy, Boston, MA (A.H.); Channing Division for Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA (B.A.R., W.C.W., Q.S., F.B.H.); Human Nutrition Unit, Faculty of Medicine and Health Sciences, Institut d'Investigació Sanitària Pere Virgili, Rovira i Virgili University, Reus, Spain (M.G.-F., J.S.-S.); Department of Preventive Medicine, University of Valencia, Spain (D.C.); Department of Preventive Medicine, University of Málaga, Spain (E.G.-G.); University Institute of Health Sciences (IUNICS), University of Balearic Islands and Hospital Son Espases, Palma de Mallorca, Spain (M.F.); Department of Internal Medicine (R.E.), Lipid Clinic, Department of Endocrinology and Nutrition Institut d'Investigacions Biomediques August Pi Sunyer (IDI- BAPS), Hospital Clinic, University of Barcelona, Spain (E.R.); Department of Family Medicine, Primary Care Division of Sevilla, San Pablo Health Center, Sevilla, Spain (J.L.); Cardiovascular and Nutrition Research Group, Institut de Recerca Hospital del Mar, Barcelona, Spain (M.F.); Department of Cardiology, University Hospital of Alava, Vitoria, Spain (F.A.); Department of Clinical Sciences, University of Las Palmas de Gran Canaria, Spain (L.S.-M.); and Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA (C.B.C.).

出版信息

Circulation. 2017 May 23;135(21):2028-2040. doi: 10.1161/CIRCULATIONAHA.116.024261. Epub 2017 Mar 9.

Abstract

BACKGROUND

Although in vitro studies and investigations in animal models and small clinical populations have suggested that ceramides may represent an intermediate link between overnutrition and certain pathological mechanisms underlying cardiovascular disease (CVD), no prospective studies have investigated the association between plasma ceramides and risk of CVD.

METHODS

The study population consisted of 980 participants from the PREDIMED trial (Prevención con Dieta Mediterránea), including 230 incident cases of CVD and 787 randomly selected participants at baseline (including 37 overlapping cases) followed for ≤7.4 years. Participants were randomized to a Mediterranean diet supplemented with extra virgin olive oil, a Mediterranean diet supplemented with nuts, or a control diet. Plasma ceramide concentrations were measured on a liquid chromatography tandem mass spectrometry metabolomics platform. The primary outcome was a composite of nonfatal acute myocardial infarction, nonfatal stroke, or cardiovascular death. Hazard ratios were estimated with weighted Cox regression models using Barlow weights to account for the case-cohort design.

RESULTS

The multivariable hazard ratios (HR) and 95% confidence intervals (CIs) comparing the extreme quartiles of plasma concentrations of C16:0, C22:0, C24:0, and C24:1 ceramides were 2.39 (1.49-3.83, <0.001), 1.91 (1.21-3.01, =0.003), 1.97 (1.21-3.20, =0.004), and 1.73 (1.09-2.74, =0.011), respectively. The ceramide score, calculated as a weighted sum of concentrations of four ceramides, was associated with a 2.18-fold higher risk of CVD across extreme quartiles (HR, 2.18; 95% CI, 1.36-3.49; <0.001). The association between baseline ceramide score and incident CVD varied significantly by treatment groups (=0.010). Participants with a higher ceramide score and assigned to either of the 2 active intervention arms of the trial showed similar CVD risk to those with a lower ceramide score, whereas participants with a higher ceramide score and assigned to the control arm presented significantly higher CVD risk. Changes in ceramide concentration were not significantly different between Mediterranean diet and control groups during the first year of follow-up.

CONCLUSIONS

Our study documented a novel positive association between baseline plasma ceramide concentrations and incident CVD. In addition, a Mediterranean dietary intervention may mitigate potential deleterious effects of elevated plasma ceramide concentrations on CVD.

CLINICAL TRIAL REGISTRATION

URL: http://www.isrctn.com. Unique identifier: ISRCTN35739639.

摘要

背景

尽管体外研究、动物模型研究及小规模临床研究表明,神经酰胺可能是营养过剩与心血管疾病(CVD)某些病理机制之间的中间环节,但尚无前瞻性研究探讨血浆神经酰胺与CVD风险之间的关联。

方法

研究人群包括来自PREDIMED试验(地中海饮食预防研究)的980名参与者,其中有230例CVD新发病例,787名在基线时随机选取的参与者(包括37例重叠病例),随访时间≤7.4年。参与者被随机分配至补充特级初榨橄榄油的地中海饮食组、补充坚果的地中海饮食组或对照饮食组。血浆神经酰胺浓度通过液相色谱串联质谱代谢组学平台进行测定。主要结局为非致死性急性心肌梗死、非致死性中风或心血管死亡的复合事件。采用加权Cox回归模型并使用Barlow权重估计风险比,以考虑病例队列设计。

结果

比较C16:0、C22:0、C24:0和C24:1神经酰胺血浆浓度极端四分位数的多变量风险比(HR)及95%置信区间(CI)分别为2.39(1.49 - 3.83,<0.001)、1.91(1.21 - 3.01,=0.003)、1.97(1.21 - 3.20,=0.004)和1.73(1.09 - 2.74,=0.011)。将四种神经酰胺浓度的加权总和计算得到的神经酰胺评分,在极端四分位数范围内与CVD风险高2.18倍相关(HR,2.18;95%CI,1.36 - 3.49;<0.001)。基线神经酰胺评分与CVD发病之间的关联在各治疗组间存在显著差异(=0.010)。神经酰胺评分较高且被分配至试验两个活性干预组之一的参与者,其CVD风险与神经酰胺评分较低者相似,而神经酰胺评分较高且被分配至对照组的参与者,其CVD风险显著更高。在随访的第一年,地中海饮食组与对照组之间神经酰胺浓度的变化无显著差异。

结论

我们的研究记录了基线血浆神经酰胺浓度与CVD发病之间新的正相关关系。此外,地中海饮食干预可能减轻血浆神经酰胺浓度升高对CVD的潜在有害影响。

临床试验注册

网址:http://www.isrctn.com。唯一标识符:ISRCTN35739639。

相似文献

引用本文的文献

本文引用的文献

5
The ART of Lowering Ceramides.降低神经酰胺的艺术。
Cell Metab. 2015 Aug 4;22(2):195-6. doi: 10.1016/j.cmet.2015.07.019.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验